Efgartigimod Offers Hope in Chronic Inflammatory Demyelinating Polyneuropathy
(MedPage Today) -- PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial.
Patients with diagnosed chronic inflammatory...
Source: MedPage Today Neurology - Category: Neurology Source Type: news